Updating results

Inebilizumab for treating neuromyelitis optica spectrum disorders [ID1529]

Proposed [GID-TA10522] Expected publication date: TBC

Technology appraisal guidance Proposed

Mirvetuximab soravtansine for previously treated platinum-resistant FR-alpha positive ovarian cancer [ID1527]

In development [GID-TA10483] Expected publication date: TBC

Technology appraisal guidance In development

Relatlimab with nivolumab for treating advanced malignant melanoma after immunotherapy in people over 12 [ID1612]

In development [GID-TA10484] Expected publication date: TBC

Technology appraisal guidance In development

Pegargiminase with pemetrexed and cisplatin for untreated advanced malignant pleural mesothelioma [ID1575]

In development [GID-TA10486] Expected publication date: TBC

Technology appraisal guidance In development

Lenalidomide with R-CHOP for untreated activated diffuse large B-cell lymphoma [ID1611]

In development [GID-TA10480] Expected publication date: TBC

Technology appraisal guidance In development

Daratumumab in combination for untreated multiple myeloma when stem cell transplant is suitable [ID1510]

In development [GID-TA10449] Expected publication date: TBC

Technology appraisal guidance In development

Apalutamide with abiraterone acetate and prednisone for treating metastatic hormone-relapsed prostate cancer [ID1480]

In development [GID-TA10465] Expected publication date: TBC

Technology appraisal guidance In development

Asthma: diagnosis, monitoring and chronic asthma management

In development [GID-NG10143] Expected publication date: 12 February 2020

NICE guideline In development

Pembrolizumab with axitinib for untreated advanced renal cell carcinoma [ID1426]

In development [GID-TA10331] Expected publication date: TBC

Technology appraisal guidance In development

Conjunctivitis: antimicrobial prescribing

In development [GID-NG10166] Expected publication date: 05 March 2021

Antimicrobial prescribing guideline In development

Stye: antimicrobial prescribing

In development [GID-NG10167] Expected publication date: TBC

Antimicrobial prescribing guideline In development

Blepharitis: antimicrobial prescribing

In development [GID-NG10168] Expected publication date: TBC

Antimicrobial prescribing guideline In development

Sodium thiosulfate for preventing hearing loss in people with cancer who are under 18 and having cisplatin chemotherapy [ID1001]

Proposed [GID-TA10611] Expected publication date: TBC

Technology appraisal guidance Proposed

Ustekinumab for treating moderately to severely active ulcerative colitis [ID1511]

In development [GID-TA10434] Expected publication date: 13 May 2020

Technology appraisal guidance In development

Skin tumours including Melanoma: assessment and management

In development [GID-NG10155] Expected publication date: 04 April 2022

NICE guideline In development

Trifluridineā€“tipiracil for treating metastatic gastric or gastro-oesophageal junction cancer after 2 or more therapies [ID1507]

In development [GID-TA10456] Expected publication date: TBC

Technology appraisal guidance In development

Galcanezumab for preventing migraine [ID1372]

In development [GID-TA10454] Expected publication date: 14 October 2020

Technology appraisal guidance In development

Nivolumab in combination for treating hormone-relapsed metastatic prostate cancer before chemotherapy [ID1619]

In development [GID-TA10490] Expected publication date: TBC

Technology appraisal guidance In development

Nivolumab in combination for treating hormone-relapsed metastatic prostate cancer after chemotherapy [ID1621]

In development [GID-TA10492] Expected publication date: TBC

Technology appraisal guidance In development

Ixazomib with lenalidomide and dexamethasone for untreated multiple myeloma [ID1170]

In development [GID-TA10254] Expected publication date: TBC

Technology appraisal guidance In development

Chronic kidney disease: assessment and management (update)

In development [GID-NG10118] Expected publication date: 18 March 2021

NICE guideline In development

High-sensitivity troponin for the early rule out of acute myocardial infarction

In development [GID-DG10035] Expected publication date: 26 August 2020

Diagnostics guidance In development

Nivolumab with temozolomide and radiotherapy for newly diagnosed glioblastoma with MGMT methylation [ID1582]

In development [GID-TA10495] Expected publication date: 19 May 2021

Technology appraisal guidance In development

Galcanezumab for preventing cluster headache [ID1212]

In development [GID-TA10425] Expected publication date: 24 February 2021

Technology appraisal guidance In development

Omalizumab for treating chronic rhinosinusitis with nasal polyps [ID1650]

Proposed [GID-TA10558] Expected publication date: TBC

Technology appraisal guidance Proposed

Ponesimod for treating relapsing multiple sclerosis [ID1393]

Proposed [GID-TA10556] Expected publication date: TBC

Technology appraisal guidance Proposed

Ofatumumab for treating relapsing multiple sclerosis [ID1677]

Proposed [GID-TA10557] Expected publication date: TBC

Technology appraisal guidance Proposed

Mexiletine for treating myotonia in adults with non-dystrophic myotonic disorders ID1488

In development [GID-TA10432] Expected publication date: 14 October 2020

Technology appraisal guidance In development

Chronic pain: assessment and management

In development [GID-NG10069] Expected publication date: 19 August 2020

NICE guideline In development

Midostaurin for treating advanced systemic mastocytosis ID1573

In development [GID-TA10503] Expected publication date: 11 November 2020

Technology appraisal guidance In development

Idebenone for treating Duchenne muscular dystrophy ID1092

In development [GID-TA10310] Expected publication date: TBC

Technology appraisal guidance In development

Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs [ID1658]

Proposed [GID-TA10561] Expected publication date: TBC

Technology appraisal guidance Proposed

Baloxavir marboxil for treating influenza [ID1537]

Proposed [GID-TA10559] Expected publication date: TBC

Technology appraisal guidance Proposed

Dapagliflozin for treating heart failure with reduced ejection fraction [ID1656]

Proposed [GID-TA10560] Expected publication date: TBC

Technology appraisal guidance Proposed

Skin abscess: antimicrobial prescribing

In development [GID-NG10163] Expected publication date: TBC

Antimicrobial prescribing guideline In development

Gosuranemab for treating progressive supranuclear palsy [ID1607]

Proposed [GID-TA10553] Expected publication date: TBC

Technology appraisal guidance Proposed

Angiotensin II for treating vasopressor-resistant hypotension caused by distributive shock ID1588

In development [GID-TA10507] Expected publication date: TBC

Technology appraisal guidance In development

Obeticholic acid for treating liver fibrosis in people with steatohepatitis [1645]

Proposed [GID-TA10606] Expected publication date: TBC

Technology appraisal guidance Proposed

Perioperative care in adults

In development [GID-NG10072] Expected publication date: 27 May 2020

NICE guideline In development

Ravulizumab for treating atypical haemolytic uraemic syndrome (aHUS) [ID1530]

Proposed [GID-TA10564] Expected publication date: TBC

Technology appraisal guidance Proposed

Roxadustat for treating anaemia in people with chronic kidney disease [ID1483]

Proposed [GID-TA10610] Expected publication date: TBC

Technology appraisal guidance Proposed

Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer [ID1516]

In development [GID-TA10468] Expected publication date: 10 June 2020

Technology appraisal guidance In development

Venous thromboembolic diseases: diagnosis, management and thrombophilia testing (2019)

In development [GID-NG10087] Expected publication date: 30 March 2020

NICE guideline In development

Lorlatinib for treating ALK-positive advanced non-small-cell lung cancer [ID1338]

In development [GID-TA10317] Expected publication date: TBC

Technology appraisal guidance In development

Pexidartinib for treating symptomatic tenosynovial giant cell tumour [ID1682]

Proposed [GID-TA10609] Expected publication date: TBC

Technology appraisal guidance Proposed

Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma [ID1576]

In development [GID-TA10463] Expected publication date: 08 April 2020

Technology appraisal guidance In development

Veliparib in combination for treating BRCA-positive, HER2-negative breast advanced cancer ID1404

In development [GID-TA10327] Expected publication date: 14 July 2021

Technology appraisal guidance In development

Entrectinib for treating ROS1-positive locally advanced or metastatic non-small-cell lung cancer [ID1541]

In development [GID-TA10415] Expected publication date: TBC

Technology appraisal guidance In development

Zynteglo for treating transfusion-dependent beta-thalassaemia ID968

In development [GID-TA10334] Expected publication date: 15 July 2020

Technology appraisal guidance In development